The research presented by Wagner et al. of 2016 [53] in which the authors discussed heterogeneous responses to TLR agonists is related to differences in the ability of CLL cells to activate BCR-related Syk kinase. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.